0001193125-23-255791.txt : 20231013 0001193125-23-255791.hdr.sgml : 20231013 20231013094729 ACCESSION NUMBER: 0001193125-23-255791 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231013 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231013 DATE AS OF CHANGE: 20231013 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Repare Therapeutics Inc. CENTRAL INDEX KEY: 0001808158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39335 FILM NUMBER: 231324069 BUSINESS ADDRESS: STREET 1: 7171 FREDERICK BANTING STREET 2: SUITE 270, BUILDING 2 CITY: SAINT-LAURENT STATE: A8 ZIP: H4S 1Z9 BUSINESS PHONE: (857) 412-7018 MAIL ADDRESS: STREET 1: 7171 FREDERICK BANTING STREET 2: SUITE 270, BUILDING 2 CITY: SAINT-LAURENT STATE: A8 ZIP: H4S 1Z9 8-K 1 d436446d8k.htm 8-K 8-K
00-0000000 0001808158 false 0001808158 2023-10-13 2023-10-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 13, 2023

 

 

Repare Therapeutics Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Québec   001-39335   Not applicable

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

7171 Frederick-Banting, Building 2

St-Laurent, Québec, Canada

   H4S 1Z9
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (857) 412-7018

Not Applicable

(Former Name or Former Address, if Changed Since Last Report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol

  

Name of each exchange

on which registered

Common shares, no par value   RPTX   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 7.01

Regulation FD Disclosure.

On October 13, 2023, Repare Therapeutics Inc. (the “Company”) issued a press release announcing the presentation of positive initial data from Modules 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, an ATR inhibitor, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston, Massachusetts. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. A copy of the presentation at the 2023 AACR-NCI-EORTC will posted on the “Investor” section of the Company’s website at https://ir.reparerx.com/news-and-events/events.

As previously announced and as described in the accompanying press release, the Company will host a conference call and live audio webcast today, October 13, 2023 at 5:30 p.m., Eastern Time, to discuss the results presented at the 2023 AACR-NCI-EORTC conference, including a discussion of additional information on its product candidate lunresertib (RP-6306) in combination with camonsertib since the September 5, 2023 data cut-off date. The live audio webcast may be accessed through the “Events & Presentations” page in the “Investors and Media” section of the Company’s website at ir.reparerx.com. Alternatively, participants may dial (877) 870-4263 (U.S. and Canada) or (412) 317-0790 (international).

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

The Company’s website and any information contained on the Company’s website are not incorporated into this Current Report on Form 8-K.

 

Item 8.01

Other Events.

On October 13, 2023, the Company reported positive initial data from Modules 1 and 2 of the Company’s ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib. The data are being presented today by Dr. Timothy A. Yap, The University of Texas MD Anderson Cancer Center, in a plenary session titled, “New Drugs on the Horizon” at the 2023 AACR-NCI-EORTC scheduled to begin at 9:40 a.m., Eastern Time. The data includes a more mature data set of more patients treated at clinically relevant doses than the data included in the abstract posted by American Association for Cancer Research on October 4, 2023.

The MYTHIC trial is a first-in-human, global, open-label Phase 1 dose-escalation clinical trial to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of lunresertib alone as a monotherapy (Module 1) or in combination with camonsertib (Module 2) in patients with advanced solid tumors harboring CCNE1 amplification or FBXW7 or PPP2R1A deleterious alterations.

The newly reported data includes assessment as of the September 5, 2023 data cut-off date for 67 patients enrolled in Module 1 and 59 patients enrolled in Module 2. The key points from the data cut are summarized below.

 

  •  

In Module 2, it was observed that the protocol-defined overall response (RECIST or GCIG CA-125 responses) of the combination therapy was 33.3% in the 18 patients evaluated at the preliminary recommended Phase 2 dose level. The clinical benefit rate (“CBR”) was defined as overall response or stable disease of at least 16 weeks without tumor progression and was 50.0% in the same patient subset.

 

  •  

It was observed that overall response in all 55 response-evaluable patients was 23.6% across all dose levels being evaluated and CBR was 41.8%.

 

  •  

In the 10 patients with gynecologic tumors treated at the preliminary recommended Phase 2 dose level, the RECIST response was 50%, overall response was 60%, and CBR was 70%. Patients in this cohort had a median of 3 and up to 9 prior lines of therapy prior to treatment with lunresertib in combination with camonsertib.

  •  

The RECIST responses in the ongoing trial also included 8 confirmed responses and 3 unconfirmed partial responses. Additionally, three patients with ovarian tumors had cancer antigen 125 (CA-125) responses.

 

  •  

RECIST responses and clinical benefit of treatment of the combination with lunresertib in combination with camonsertib was seen across all three lunresertib-sensitizing alterations: CCNE1 amplification, FBXW7 or PPP2R1A deleterious alterations. Molecular response rate (“MRR”) was observed to be significantly higher in the combination therapy module of the trial (Module 2), as compared to the monotherapy module of the trial (Module 1) (p=0.003), providing further evidence of enhanced anti-tumor activity, MRR in the combination therapy module was observed to be 50% (n=24), as compared to 10% (n=30) observed in the lunresertib monotherapy module.

 

  •  

In Module 2, encouraging and highly manageable safety and tolerability data was observed for 59 patients enrolled in the combination therapy module. The most common treatment-related adverse event (“TRAE”) observed was anemia, with Grade 3 occurring in 42% of patients enrolled in Module 2. Further, anemia usually improved for patients with a one-week treatment interruption and standard supportive care, and, notably, anemia did not lead to any therapy discontinuations of treatment at the preliminary recommended Phase 2 dose level. There were no Grade 4 or Grade 5 TRAEs reported at the preliminary recommended Phase 2 dose level.

 

  •  

Data indicates that anemia management may be individualized and alleviated with patient monitoring. This approach is now being tested in the MYTHIC trial.

 

  •  

35% of patients in the MYTHIC trial in Module 2 did not develop anemia at the preliminary recommended Phase 2 dose level. Generally, those patients who developed Grade 3 anemia had the lowest hemoglobin values at entry into the trial, were intensely pretreated prior to trial enrollment with greater than four prior therapies and were of advanced age.

Clinical proof of concept was established in the MYTHIC trial for both lunresertib alone as a monotherapy and in combination with camonsertib. Further, the Company believes that the MYTHIC trial is the first clinical proof-of-concept for a synthetic lethal strategy with a PKMYT1 inhibitor combined with an ATR inhibitor in patients with molecularly-selected cancers.

Patient enrollment in the MYTHIC trial is ongoing, with the goal of optimizing the schedule for the combination module and to further investigate the promising antitumor signals seen to date in a larger number of patients with selected tumors and genomic alterations. The Company expects to complete multiple expansions of the MYTHIC trial and report additional data from the MYTHIC trial in the second half of 2024, with later-stage trials expected to initiate shortly thereafter.

Cautionary Regarding Forward-Looking Statements

Certain statements in this Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this Current Report on Form 8-K other than statements of historical facts are “forward-looking statements. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the timing, safety, efficacy, clinical progress and results of the monotherapy of lunresertib and the combination therapy of lunresertib and camonsertib, and proposed further development of the combination therapy of lunresertib and camonsertib. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this Current Report on Form 8-K. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including the COVID-19 pandemic, the conflict in Ukraine, rising inflation, and uncertain credit and financial markets on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other

factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (“SEC”) and the Québec Autorité des Marchés Financiers (“AMF”) on February 28, 2023, and its other documents subsequently filed with or furnished to the SEC and AMF including the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 filed with the SEC on August 9, 2023. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

 

Item 9.01

Financial Statements and Exhibit.

(d) Exhibits

 

Exhibit

No.

   

Description

99.1    Press Release dated October 13, 2023
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      REPARE THERAPEUTICS INC.
Date: October 13, 2023     By:  

/s/ Lloyd M. Segal

      Lloyd M. Segal
      President and Chief Executive Officer
 EX-99.1 2 d436446dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial

Evaluating Lunresertib Alone and in Combination with Camonsertib

Lunresertib + camonsertib combination demonstrated clear signals of anti-tumor activity across

multiple tumor types and all selected genotypes

Overall response of 33.3% across all tumor types and 50% RECIST response in patients with

heavily pre-treated gynecologic tumors, including endometrial, ovarian and cervical, at the

preliminary recommended phase 2 dose

Encouraging safety and tolerability profile observed as monotherapy and in combination with

camonsertib

Repare to host conference call and webcast today at 5:30 p.m.ET to discuss these results

CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE)—October 13, 2023— Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported positive initial data from Modules 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, an ATR inhibitor. The data are being presented in a plenary session titled, “New Drugs on the Horizon” at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston, Mass.

Lunresertib (RP-6306) is a first-in-class precision oncology small molecule PKMYT1 inhibitor that targets CCNE1 amplification, FBXW7 and PPP2R1A alterations in solid tumors. Lunresertib is being evaluated alone and in combination with camonsertib (RP-3500 / RG6526), a potent and selective oral inhibitor of ATR developed by Repare and now partnered with Roche for development excluding the lunresertib + camonsertib combination.

“We’re excited by these first clinical proof-of concept results and believe that they further validate the pipeline power of our SNIPRx discovery platform and demonstrate the potential of lunresertib as the only clinical-stage PKMYT1 inhibitor,” said Lloyd M. Segal, President and Chief Executive Officer of Repare. “We saw early efficacy signals across multiple tumor types and in each genotype selected, most notably in gynecological tumors where the lunresertib + camonsertib combination provides a potential new treatment option for these patients. Today is an important step forward in Repare’s mission to deliver next-generation precision oncology medicines to patients with genomically-defined tumor alterations predicted by our platform to respond to our candidate drugs.”

“The data presented today, although early, are highly promising as lunresertib in combination with camonsertib results in clear clinical activity across several tumor types and genotypes along with a favorable safety and tolerability profile,” said Dr. Timothy A. Yap, MBBS, PhD, FRCP, Professor in the Department of Investigational Cancer Therapies (Phase 1 Program) and Vice President, Head of Clinical Development in the Therapeutics Discovery Division at The University of Texas MD Anderson Cancer Center and Principal

Investigator on the MYTHIC trial. “These early data suggest treatment with lunresertib in combination with camonsertib could result in efficacy outcomes for patients in the gynecological cancer setting, an area where we’re still seeing unmet patient needs despite current therapies.”

Key Initial Findings from the Phase 1 MYTHIC Clinical Trial:

MYTHIC (NCT: NCT04855656), a first-in-human, global, open-label Phase 1 dose-escalation clinical trial to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of lunresertib as a monotherapy (Module 1) or in combination with camonsertib (Module 2) in patients with advanced solid tumors harboring CCNE1 amplification or FBXW7 or PPP2R1A deleterious alterations achieved clinical proof of concept. As of September 5, 2023, the cutoff date for the data presented at the AACR-NCI-EORTC conference, 67 patients were enrolled in Module 1 and 59 patients in Module 2.

 

  •  

Protocol-defined overall response (OR) (RECIST or GCIG CA-125 responses) at the combination preliminary recommended phase 2 dose (RP2D) was 33.3% (N=18); CBR at the combination preliminary RP2D (overall response or stable disease of at least 16 weeks without tumor progression) was 50.0%. In all evaluable patients, across all doses (N-55), OR was 23.6% and CBR was 41.8%.

 

  •  

In patients with gynecologic tumors at the combination preliminary RP2D (N=10), the RECIST response was 50%, OR 60%, and CBR 70%. Patients in this cohort had a median of 3 and up to 9 prior lines of therapy.

 

  •  

RECIST responses in this ongoing combination trial included 8 confirmed and 3 unconfirmed partial responses (PR). Additionally, 3 patients with ovarian tumors had cancer antigen 125 (CA-125) responses.

 

  •  

RECIST responses and clinical benefit with combination therapy was seen across all 3 lunresertib-sensitizing alterations: CCNE1 amplification or FBXW7 or PPP2R1A deleterious alterations. Molecular response rate (MRR) was significantly higher in combination compared to monotherapy (p=0.003), providing further evidence of enhanced anti-tumor activity: observed MRR in combination therapy was 50% (n=24), compared to 10% (n=30) with lunresertib monotherapy.

 

  •  

Encouraging and highly manageable safety and tolerability was observed for the combination therapy (n=59). The most common treatment-related adverse event (TRAE) was anemia, with grade 3 occurring in 42% of patients:

 

  •  

Anemia usually improved with a one-week treatment interruption and standard supportive care and did not lead to any therapy discontinuations at preliminary RP2D.

 

  •  

There were no Grade 4 or Grade 5 TRAEs reported at preliminary RP2D.

 

  •  

Data clearly indicates that anemia management can be individualized and alleviated with simple patient monitoring. This approach is now being tested in the MYTHIC trial.

 

  •  

35% of patients did not develop anemia at preliminary RP2D. Generally, those with grade 3 anemia had the lowest hemoglobin values at entry, were intensely pretreated with >4 prior therapies and were of advanced age.

 

  •  

Achieved the first clinical proof-of-concept for a synthetic lethal strategy with a PKMYT1 inhibitor combined with an ATR inhibitor in patients with molecularly-selected cancers.

  •  

Patient enrollment in MYTHIC continues both to optimize the schedule for the combination and to further investigate the promising antitumor signals seen to date in a larger number of patients with selected tumors and genomic alterations.

“The encouraging Phase 1 safety and tolerability profile and early antitumor efficacy data provide proof of concept for lunresertib and clear direction for further development of the chemotherapy-free combination of lunresertib + camonsertib to selectively target the lunresertib-relevant alterations across multiple tumor types, including line of sight on later stage randomized or otherwise definitive studies as the data continue to mature,” said Maria Koehler, MD, PhD, Chief Medical Officer of Repare. “This novel, orally delivered combination may provide new therapeutic options in areas of high unmet need, and we look forward to completing the multiple expansions of the Phase 1 MYTHIC study and reporting results in 2024 with later-stage trials expected to initiate shortly thereafter.”

Company Virtual Webcast Event:

Repare will host a conference call and webcast today, October 13, 2023, at 5:30 p.m. Eastern Time to discuss the results presented at the AACR-NCI-EORTC conference, including updated data since the September 5, 2023 data cutoff. Repare’s executive management team will be joined by Dr. Timothy A. Yap, MBBS, PhD, FRCP, Principal Investigator, Professor in the Department of Investigational Cancer Therapies (Phase 1 Program) and Vice President, Head of Clinical Development in the Therapeutics Discovery Division at the University of Texas MD Anderson Cancer Center in Houston, Texas.

To access the call, please dial (877) 870-4263 (U.S. and Canada) or (412) 317-0790 (international) at least 10 minutes prior to the start time and ask to be joined to the Repare Therapeutics call. A live webcast will be available in the Investor section of the Company’s website at https://ir.reparerx.com/events-and-presentations/events . A webcast replay will also be archived for at least 30 days.

About Repare Therapeutics’ SNIPRx® Platform

Repare’s SNIPRx® platform is a genome-wide CRISPR-based screening approach that utilizes proprietary isogenic cell lines to identify novel and known synthetic lethal gene pairs and the corresponding patients who are most likely to benefit from the Company’s therapies based on the genetic profile of their tumors. Repare’s platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx® screening, in order to selectively target those tumors in patients most likely to achieve clinical benefit from resulting product candidates.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1 clinical development; camonsertib (also known as RP-3500 or RG6526), a potential leading ATR inhibitor currently in Phase 1/2 clinical development and partnered with Roche; RP-3467, a preclinical Polq inhibitor program; as well as several additional, undisclosed preclinical programs, including RP-1664. For more information, please visit reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.

SNIPRx® is a registered trademark of Repare Therapeutics Inc.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are “forward-looking statements. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the safety, efficacy and clinical progress of the Company’s clinical programs, including lunresertib and camonsertib; and proposed further development of the combination therapy of lunresertib and camonsertib. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including the COVID-19 pandemic, the conflict in Ukraine, rising inflation, and uncertain credit and financial markets on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (“SEC”) and the Québec Autorité des Marchés Financiers (“AMF”) on February 28, 2023, and its other documents subsequently filed with or furnished to the SEC and AMF including the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 filed with the SEC on August 9, 2023. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit reparerx.com and follow Repare on Twitter at @RepareRx and on LinkedIn at https://www.linkedin.com/company/repare-therapeutics/.

Repare Contact:

Steve Forte Executive

Vice-President and Chief Financial Officer

Repare Therapeutics Inc.

investor@reparerx.com

Investors:

Matthew DeYoung

Argot Partners

repare@argotpartners.com

Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

EX-101.SCH 3 rptx-20231013.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 rptx-20231013_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Securities Act File Number Securities Act File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Country Entity Address, Country Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 5 rptx-20231013_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g436446snap1.jpg GRAPHIC begin 644 g436446snap1.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Oct. 13, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Oct. 13, 2023
Entity Registrant Name Repare Therapeutics Inc.
Entity Incorporation, State or Country Code A8
Securities Act File Number 001-39335
Entity Tax Identification Number 00-0000000
Entity Address, Address Line One 7171 Frederick-Banting
Entity Address, Address Line Two Building 2
Entity Address, City or Town St-Laurent
Entity Address, State or Province QC
Entity Address, Country CA
Entity Address, Postal Zip Code H4S 1Z9
City Area Code 857
Local Phone Number 412-7018
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common shares, no par value
Trading Symbol RPTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001808158
Amendment Flag false
XML 8 d436446d8k_htm.xml IDEA: XBRL DOCUMENT 0001808158 2023-10-13 2023-10-13 00-0000000 0001808158 false 8-K 2023-10-13 Repare Therapeutics Inc. A8 001-39335 7171 Frederick-Banting Building 2 St-Laurent QC CA H4S 1Z9 857 412-7018 false false false false Common shares, no par value RPTX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( .Y-35<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #N34U70\NI4NX K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>*$[&"B;-I66G#08K;.QF;+4UC6-C:R1]^SE>FS*V!]C1TN]/ MGT"M\D*Y@"_!>0QD,-Y-MA^B4'[-CD1> $1U1"MCF1)#:NY=L)+2,QS 2W62 M!X2ZJA[ (DDM2<(,+/Q"9%VKE5 !);EPP6NUX/UGZ#-,*\ >+0X4@9<<6#=/ M].>I;^$&F&&$P<;O NJ%F*M_8G,'V"4Y1;.DQG$LQR;GT@X%;S9\4;621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M .Y-35>*!XTZ?@0 -01 8 >&PO=V]R:W-H965T&UL MG9AA9RR6^V.UUKM,/,LA&$T!4$G'R M[[L"!WP-7MSF0XQ >GE8K=X5C+92/>F(DCC58R M\EANQPYUWDX\BDUD[ EW,LK8AB^X^2V;*VBYE4HH$IYJ(5.B^'KL3.G%I7]F M!Q0]?A=\J_>.B7V4E91/MG$;CAW/$O&8!\9*,/AYYC,>QU8)./[>B3K5/>W M_>,W]9OBX>%A5DSSF8R_B=!$8V?HD)"O61Z;1[G]Q'][ *Q-\ ?'AC@[P;X!7=YHX+RBADV&2FY)Q7=U@ M)WA9"OH'!!\"19TQQLHRX8AG/C0@T)&IPBB">58AGQR""FE295$7BGY"%@0 2JHR(('N1)&<$VF@2$W(N;D/D]67#4!X5J>1SO=\VZW MCW -*Z[A,9%;LA=R&T+^B;4(BO A=+BBYW6\\@_!.Z_PSH_!FX8AK'M]\G9 M[J ?>4@;9Q-7'- !)3>*A[#.@J?.)>2S2#<(*O5J(_;^/^QR*QNM&)>\S$4< M E]I=CZ&N50.QA=72PHZO7OZ*I%/%?R M6:1!XY2W:'Z=86AUG:"XT[\+7&DKC4"XTFR* =4U@^)6_V^@N=2&Q>2[R Y: M78OBI]Z"T._G&%U=-BCN]T5>36&C>1@&%QCV!QA(71PH;N!W,H"HS".98I[; M(M*C?F?@4:P6T+H84-S!OT$I,#R%P"1)GNX<5S=2X4)K%FN.(=5U@.*VO9"Q M"(3U0O(%5IP2+&[DP55:>6KCI[A/SQ7O!! >#DN^W)WQ%#R;/*S7!^8/UVLC M\VN;]W%/?D=VJW4.9&V +;*M@+7!^[@C+X6!W85<$^K_O/J%[+8>C3[5HF3S M$[8".H*-&_A+*@ELX<@SBW.4=._- #?FI6*VNI'%:[*2C?G6(O X7_Z!D=3> M[N.._!8D]$\P@_15XZRUD_@OYS)NA<"G8*-*A-Z1]S%K]VNS]EMTZ M+,FP6)8W,=LT\N "!X/D[KVCV^\=7YB=%DUBO@8A[W0 SZG*3PAEP\BL>&U? M26-D4AQ&G(%'V YP?2VE>6O8+P'5AYS)/U!+ P04 " #N34U7GZ ;\+$" M #B# #0 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+3 M8JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A M8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72L MJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GT MA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WAT MUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:I MKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PEY7>>9 M]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NX MZBQ_AOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8; M9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%' MGL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G M)$WS/(X %F>0IA@"IQ%', ; 4/2='@//GL?)=-[*CG_5U/\!%!+ P04 M" #N34U7EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q="> M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C] M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA< MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X M4$L#!!0 ( .Y-35<<.&7J/P$ #P" / >&PO=V]R:V)O;VLN>&UL MC5'+;L) #/R5U7Y $U"+5$2XE#Z0JA:5BON2=8C%/B*O RU?7R=15*1>>O)Z M;(UG9A?G2,=]C$?UY5U(A:Z9FWF6I;(&;])-;"#(I(KD#4M+ARPU!,:F&H"] MRZ9Y/LN\P:"7BY%K0]EU$QE*QA@$[( =PCG]SKM6G3#A'AWR=Z'[MP.M/ ;T M> %;Z%RK5,?S2R2\Q,#&;4N*SA5Z,@QV0(SE'WC;B?PT^]0C;/8?1H04>I8+ M8864N-_H^8UH/($L#UW+\0D= ZT,PS/%ML%PZ&C$179EH\]AK$.(<_I/C+&J ML(15+%L/@8<<"5PG,*0:FZ15,!X*/:XH$ZQZ#"PAJ748J&2WEYIK=WDWM)J'7N0;#W\!J-'[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E* M%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1,) MKM\,<'AT_@%02P,$% @ [DU-5V60>9(9 0 SP, !, !;0V]N=&5N M=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2 MVS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\ MFK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP39G 8ED\C<+,:DH9 MHS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM M0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I- M"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O& M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4 " #N34U7!T%-8H$ M "Q $ @ $ 9&]C4')O<',O87!P+GAM;%!+ 0(4 M Q0 ( .Y-35=#RZE2[@ "L" 1 " :\ !D;V-0 M97)PC$ 8 )PG 3 M " &UL4$L! A0#% @ M[DU-5XH'C3I^! U!$ !@ ("!#0@ 'AL+W=O&UL4$L! A0#% @ [DU-5Y>* MNQS $P( L ( !G0\ %]R96QS+RYR96QS4$L! A0# M% @ [DU-5QPX9>H_ 0 / ( \ ( !AA 'AL+W=O M7!E&UL4$L%!@ ) D /@( "$4 $! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d436446d8k.htm rptx-20231013.xsd rptx-20231013_lab.xml rptx-20231013_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d436446d8k.htm": { "nsprefix": "rptx", "nsuri": "http://www.reparerx.com/20231013", "dts": { "inline": { "local": [ "d436446d8k.htm" ] }, "schema": { "local": [ "rptx-20231013.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "rptx-20231013_lab.xml" ] }, "presentationLink": { "local": [ "rptx-20231013_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-10-13_to_2023-10-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d436446d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-10-13_to_2023-10-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d436446d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "terseLabel": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.reparerx.com//20231013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001193125-23-255791-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-255791-xbrl.zip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end